Mayzent Approved for Relapsing MS
"Multiple sclerosis can have a profound impact on a person's life," said Dr. Billy Dunn, director of the agency's Division of Neurology Products.
MS is an autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. Most people have initial symptoms between the ages of 20 and 40, and MS strikes more women than men, the FDA said in a news release.
Many people with MS are left permanently disabled and worsen over time, the agency said.
Mayzent's effectiveness was shown in clinical studies of 1,651 people. Progression of disability was significantly lower among those who took Mayzent than in a group that took a placebo. Mayzent also decreased the number of relapses, the FDA said.
The drug must be accompanied by a patient medication guide that describes the medication's uses and risks. Since Mayzent may raise the risk of infections, users should have a complete blood count before treatment starts. And users should contact their doctor if they have any vision changes, changes in heart rate or trouble breathing, the FDA said.
Since Mayzent may harm a developing fetus, women of childbearing age should use contraception during treatment and for 10 days after stopping the drug.
Mayzent's most common side effects include headache, high blood pressure and liver problems.
The medication is produced by the Swiss drugmaker Novartis.
© 2020 HealthDay. All rights reserved.
Posted: March 2019
Read this next
FRIDAY, Sept. 18, 2020 -- Pregnancy can delay the onset of multiple sclerosis (MS) by more than three years, researchers report. The international study found those who'd been...
TUESDAY, Sept. 15, 2020 -- More than three-quarters of Americans with multiple sclerosis (MS) experience financial difficulties that often prevent them from getting treatment, new...
WEDNESDAY, Aug. 26, 2020 -- High rates of child and teen obesity could play a growing role in people's risk for multiple sclerosis (MS), British researchers say. Prior research...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.